Pharma Investments, Ventures & Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Investments, Ventures & Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Acorda Therapeutics, Inc.
Acorda Therapeutics Names John Librie Senior Vice President, Sales and Marketing
April 20th, 2008
Acorda Therapeutics, Inc. (NASDAQ: ACOR) announced that John Librie has been promoted to Senior Vice President, Sales and Marketing. Mr. Librie will continue to manage the sales and marketing efforts of Zanaflex Capsules(R) (tizanidine hydrochloride), as well as oversee all pre-commercial and commercial initiatives around the Company's lead development compound, Fampridine-SR. Fampridine-SR is a sustained-release tablet being studied to evaluate its safety and efficacy in improving walking ability in people with multiple sclerosis (MS). "John has done an outstanding job in helping to build out Acorda's overall commercial capability. Under his leadership, Acorda has...
Source: Pharma Investments, Ventures & Law Weekly (2008-04-20)
|
